These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23406693)

  • 1. Low-molecular-weight heparin use with thrombolysis: is it effective and safe? Ten years' clinical experience.
    Ucar EY; Araz O; Akgun M; Meral M; Kalkan F; Saglam L; Kaynar H; Gorguner AM
    Respiration; 2013; 86(4):318-23. PubMed ID: 23406693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Controversies in Thrombolytic Use in Acute Pulmonary Embolism.
    Long B; Koyfman A
    J Emerg Med; 2016 Jul; 51(1):37-44. PubMed ID: 27071316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should Low-Molecular-Weight Heparin be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?
    Senturk A; Ucar EY; Berk S; Ozlu T; Altınsoy B; Dabak G; Cakır E; Kadıoglu EE; Sen HS; Ozsu S;
    Clin Appl Thromb Hemost; 2016 May; 22(4):395-9. PubMed ID: 25630985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants.
    Matute MC; Masjuan J; Egido JA; Fuentes B; Simal P; Díaz-Otero F; Reig G; Díez-Tejedor E; Gil-Nuñez A; Vivancos J; Alonso de Leciñana M
    Cerebrovasc Dis; 2012; 33(3):231-9. PubMed ID: 22261670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and low molecular weight heparin in older people in a hospital with ambulatory care.
    Chan DK; Ong B; Almafragy H; Karr M; Hung AW; Liu JG
    Arch Gerontol Geriatr; 2006; 43(2):233-41. PubMed ID: 16359739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism.
    Graif A; Kimbiris G; Grilli CJ; Agriantonis DJ; Putnam SG; Leung DA
    J Vasc Interv Radiol; 2020 Apr; 31(4):537-543. PubMed ID: 31959518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evidence-based guidelines for prevention and therapy of venous thromboembolism].
    Falciani M; Dilaghi B; Conti AA; Caciolli S; Gensini GF
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):27-35. PubMed ID: 11253337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombolysis in pulmonary embolism - initial experience].
    Galrinho A; Ferreira D; Abreu A; Santos L; Prazeres-Sá E; Ferreira R
    Rev Port Cardiol; 1999 Jan; 18(1):37-42. PubMed ID: 10091523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
    Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E
    Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].
    Zhai ZG; Wang C; Liu YM; Qin ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):221-6. PubMed ID: 15266820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indigenous and imported low molecular weight heparin in the treatment of chronic hepatitis B and cirrhosis with hepatitis B virus: a prospective randomized controlled clinical study].
    Huang JS; Luo X; Yu JX; Liu W; Chen XW; Xie L; Zhu XY; Chen GY
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):408-11. PubMed ID: 17631708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry.
    Bruscas MJ; Nieto JA; Perez-Pinar M; López-Jiménez L; Fernández-Capitán C; López-Chuliá F; Orue-Lecue MT;
    Ann Hematol; 2007 Jul; 86(7):519-26. PubMed ID: 17437112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism.
    Zhang LY; Gao BA; Jin Z; Xiang GM; Gong Z; Zhang TT; Lu HF; Wang YQ; Gong Y; Lu C; Huang WL
    Saudi Med J; 2018 Nov; 39(11):1090-1095. PubMed ID: 30397707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice patterns and complication rates of thrombolysis for pulmonary embolism.
    Bradford MA; Lindenauer PK; Walkey AJ
    J Thromb Thrombolysis; 2016 Oct; 42(3):313-21. PubMed ID: 26961258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
    Spyropoulos AC; Turpie AG; Dunn AS; Spandorfer J; Douketis J; Jacobson A; Frost FJ;
    J Thromb Haemost; 2006 Jun; 4(6):1246-52. PubMed ID: 16706967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Three patients with massive pulmonary embolism].
    Oostenbrug LE; van der Werf TS; Tulleken JE; Zijlstra JG; Fijen JW; Ligtenberg JJ
    Ned Tijdschr Geneeskd; 2001 Jul; 145(27):1277-81. PubMed ID: 11475016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.